Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...

Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...

Moderna, Inc. (MRNA) shares were up over 3% in choppy trading on Friday afternoon, even as the biotech firm reported a ...

A social media post claims that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic. After fact checking, ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The vaccine maker posted a loss of $2.91 per share for the quarter, exceeding analysts' estimates of a $2.73 per share loss. Revenue came in at $966 million, below the consensus forecast of $995.44 ...

Explore the truth behind false claims that Moderna's CEO confessed to creating a COVID-19 vaccine before the pandemic, and the context of his remarks on vaccine production.